CART (85-102)-inhibition of psychostimulant-induced hyperlocomotion: importance of cyclization

Synthetic derivative of C-terminal fragment of CART (55–102) with reduced thiol groups, [Abu^86,94]CART (85–102)_red, given together with amphetamine (5 mg/kg, s.c.) or cocaine (15 mg/kg, s.c.), reversed hyperlocomotion induced by these drugs at a dose of 0.1 μg but not at a higher dose. In the cerebral cortex homogenate, [Abu^86,94]CART (85–102)_red was nonspecifically cleaved from N- and C-termini. This peptide contains two chemically blocked Cys residues, and two others in reduced form. Concomitant with cleavage, rapid cyclization occurred. The newly formed cyclic peptides were stable. The cyclic peptide [Abu^86,94]CART (85–102)_ox failed to inhibit amphetamine- and cocaine-induced locomotor activity. The ability to inhibit the locomotor-stimulant activity of amphetamine was retained in [Abu^86,88,94,101]CART (85–102), in which all Cys were replaced with 2-aminobutyric acid to prevent their pairing. Disulfide bridge formation may be an interesting mechanism that prevents proteolysis of [Abu^86,94]CART (85–102)_red and terminates its ability to reverse amphetamine-induced hyperlocomotion.     

Acetyl-RYYRIK-NH(2) is a highly efficacious OP(4) receptor agonist in the cardiovascular system of anesthetized rats

Nociceptin, the endogenous ligand of the OP₄ or ORL₁ (opioid receptor-like₁) receptor, decreases blood pressure and heart rate in anesthetized rats. Since the OP₄ receptor antagonist [Phe¹Ψ(CH₂-NH)Gly²]-nociceptin(1–13)NH₂ possesses an agonistic effect in this model, we examined whether other purported OP₄ receptor antagonists, acetyl-RYYRIK-NH₂ and naloxone benzoylhydrazone, antagonize the depressant effects of nociceptin. Acetyl-RYYRIK-NH₂, like nociceptin and [Phe¹Ψ(CH₂-NH)Gly²]-nociceptin(1–13)NH₂ and unlike naloxone benzoylhydrazone, decreased diastolic blood pressure and heart rate (rank order of potencies: nociceptin ≈ acetyl-RYYRIK-NH₂ [Phe¹Ψ(CH₂-NH)Gly²]-nociceptin(1–13)NH₂). The depressant effects were insensitive to the OP_1–3 receptor antagonist naloxone but diminished by naloxone benzoylhydrazone. In conclusion, the hypotensive and bradycardic effects of nociceptin in the anesthetized rat are mediated via OP₄ receptors, at which acetyl-RYYRIK-NH₂ is a highly potent and efficacious agonist.     

Interaction of ovokinin(2-7) with vascular bradykinin 2 receptors

Intravenous administration of ovokinin(2–7), a cleavage peptide derived from ovalbumin, dose-dependently (0.1–5 mg/kg) lowered the mean arterial pressure (MAP) that was not accompanied by a significant change in the heart rate (HR) of urethane-anesthetized rats. The hypotensive effects of ovokinin(2–7) were five orders of magnitude lower compared to that of bradykinin and were largely prevented by pretreatment with the bradykinin B₂ receptor antagonist HOE140 (81.6±18.4%) and moderately affected by the B₁ receptor antagonist [des-Arg¹⁰]-HOE140 (26.3±15.5%). Intracellular Ca²⁺ levels, as measured by Fur 2-AM, were significantly elevated in cultured aorta smooth muscle cells by ovokinin(2–7). The increases were abolished by HOE140 and unaffected by [des-Arg¹⁰]-HOE140. The elevation of intracellular Ca²⁺ by ovokinin(2–7) was dependent on Ca²⁺ entry from extracellular space as it was reduced in a Ca²⁺-free solution. Pretreatment of the cells with the phospholipase C inhibitor U73122 (2 μM) eliminated the Ca²⁺ increase by the peptide. PA phosphohydrolase and phospholipase A₂ inhibitors significantly reduced the responses as well. Our results show that ovokinin(2–7) modulates cardiovascular activity by interacting with B₂ bradykinin receptors.     

Phosphoinositide hydrolysis increase by angiotensin-(1--7) in neonatal rat brain

Angiotensin (Ang)-(1–7) is an endogenous peptide hormone of the renin–angiotensin system which exerts diverse biological actions, some of them counterregulate Ang II effects. In the present study potential effect of Ang-(1–7) on phosphoinositide (PI) turnover was evaluated in neonatal rat brain. Cerebral cortex prisms of seven-day-old rats were preloaded with [³H]myoinositol, incubated with additions during 30 min and later [³H]inositol-phosphates (IPs) accumulation quantified. It was observed that PI hydrolysis enhanced 30% to 60% in the presence of 0.01 nM to 100 nM Ang-(1–7). Neither 10 nM [D-Ala⁷]Ang-(1–7), an Ang-(1–7) specific antagonist, nor 10 nM losartan, an angiotensin II type 1 (AT₁) receptor antagonist, blocked the effect of 0.1 nM Ang-(1–7) on PI metabolism. The effect of 0.1 nM Ang-(1–7) on PI hydrolysis was not reduced but it was even significantly increased in the simultaneous presence of [D-Ala⁷]Ang-(1–7) or losartan. PI turnover enhancement achieved with 0.1 nM Ang-(1–7) decreased roughly 30% in the presence of 10 nM PD 123319, an angiotensin II type 2 (AT₂) receptor antagonist. The antagonists alone also enhanced PI turnover. Present findings showing an increase in PI turnover by Ang-(1–7) represent a novel action for this peptide and suggest that it exerts a function in this signaling system in neonatal rat brain, an effect involving, at least partially, angiotensin AT₂ receptors.     

Synthesis and solution behavior of the trinuclear palladium(II) unsaturated carboxylate complexes triangle-Pd3[μ-O2CC(R′) = CHMe]6 (R′ = Me, H): X-ray structure of palladium(II) tiglate (R′ = Me)

The first examples of binary palladium(II) derivatives of unsaturated carboxylic acids are reported. It was found that the interaction of Pd₃(μ-OAc)₆ with the ,β-unsaturated 1-methylcrotonic (tiglic) and crotonic acids leads to the corresponding carboxylates of composition Pd₃[μ-O₂CC(R′) = CHMe]₆, where R′ = Me (1) or H (2). The new compounds have been characterized by elemental analysis, solid and solution IR, ¹H and ¹³C NMR, and ESI mass spectrometry. The crystal structure of 1 has been determined. This molecule displays a central Pd₃ cyclic core with Pd–Pd distances of 3.093–3.171 Å. Each Pd–Pd bond is bridged by a pair of carboxylate ligands, one above and the other below the Pd₃ plane, providing a square planar coordination for each Pd atom in an approximate D_3h overall symmetry arrangement. Solution spectroscopic data show that the bridging η¹:η¹:μ₂ interaction of the carboxylates of 1 and 2 is readily displaced, with a change of the ligand to the terminal (η¹) coordination mode.     

Phosphinic,phosphonic and seleninic acid bioisosteres of isonipecotic acid as novel and selective GABA(C) receptor antagonists

A number of amino acids bioisosterically derived from the specific GABA_A agonist, isonipecotic acid, were electrophysiologically characterized as antagonists at GABA_C ρ₁ receptors expressed in Xenopus oocytes. The phosphinic acid analogue of isonipecotic acid, piperidin-4-ylphosphinic acid (2), was comparable with the standard GABA_C antagonist, (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA), in terms of potency and GABA_C versus GABA_A receptor selectivity. Whereas the phosphonic acid analogue, piperidin-4-ylphosphonic acid (4), was at least an order of magnitude weaker than piperidin-4-ylphosphinic acid as a GABA_C antagonist, the seleninic acid analogue, piperidin-4-ylseleninic acid (SEPI, 6), was the most potent and selective GABA_C antagonist within the group of isonipecotic acid derived amino acids studied.     

Bradykinin counteracts the stimulatory effect of angiotensin-(1-7) on the proximal tubule Na+ -ATPase activity through B2 receptor

Recently, we demonstrated that angiotensin-(1–7) (Ang-(1–7)) stimulates the Na⁺-ATPase activity through a losartan-sensitive angiotensin receptor, whereas bradykinin inhibits the enzyme activity through the B₂ receptor [Regul. Pept. 91 (2000) 45; Pharmacol. Rev. 32 (1980) 1]. In the present paper, the effect of bradykinin (BK) on Ang-(1–7)-stimulated Na⁺-ATPase activity was evaluated. Preincubation of Na⁺-ATPase with 10⁻⁹ M Ang-(1–7) increases enzyme activity from 7.9±0.9 to 14.1±1.5 nmol Pi mg⁻¹ min⁻¹, corresponding to an increase of 79% (p<0.05). This effect is reverted by bradykinin in a dose-dependent manner (10⁻¹⁴–10⁻⁸ M), reaching maximal inhibitory effect at 10⁻⁹ M. Des-Arg⁹ bradykinin (DABK), an agonist of B₁ receptor, at the concentrations of 10⁻⁹–10⁻⁷ M, does not mimic the BK inhibitory effect, and des-Arg⁹-[Leu⁸]-BK (DALBK), a B₁ receptor antagonist, at the concentrations of 10⁻¹⁰–10⁻⁷ M, does not prevent the inhibitory effect of BK on Ang-(1–7)-stimulated enzyme. On the other hand, HOE 140, an antagonist of B₂ receptor, abolishes the inhibitory effect of BK on the Ang-(1–7)-stimulated enzyme in a dose-dependent manner, reaching maximal effect at 10⁻⁷ M. Taken together, these data indicate that stimulation of B₂ receptors by BK can counteract the stimulatory effect of Ang-(1–7) on the proximal tubule Na⁺-ATPase activity.     

Novel oxotremorine-related heterocyclic derivatives: Synthesis and in vitro pharmacology at the muscarinic receptor subtypes

A set of novel heterocyclic ligands (6–27) structurally related to Oxotremorine 2 was designed, synthesized and tested at muscarinic receptor subtypes (mAChRs). In the binding experiments at cloned human receptors (hm1–5), compounds 7 and 15 evidenced a remarkable affinity and selectivity for the hm2 subtype. The in vitro functional assays, performed on a selected group of derivatives at M₁, M₂, and M₃ tissue preparations, singled out the 3-butynyloxy-5-methylisoxazole trimethylammonium salt 7 as a potent unselective muscarinic agonist [pEC₅₀: 7.40 (M₁), 8.18 (M₂), and 8.14 (M₃)], whereas its 5-phenyl analogue 12 behaved as a muscarinic antagonist, slightly selective for the M₁ subtype [pK_B: 6.88 (M₁), 5.95 (M₂), 5.53 (M₃)]. Moreover, the functional data put in evidence that the presence of the piperidine ring may generate a functional selectivity, e.g., an M₁ antagonist/M₂ partial agonist/M₃ full agonist profile (compound 21), at variance with the corresponding quaternary ammonium salt (compound 22) which behaved as a muscarinic agonist at all M_1–3 receptors, with an appreciable selectivity for the cardiac M₂ receptors.     

Synthesis, immobilization and catalytic activity of some silylated cyclopentadienyl rhodium(I) complexes

The mixture of isomers of silylated cyclopentadiene derivative C₅H₅CH₂CH₂Si(OMe)₃ (1) has been used for the syntheses of the mononuclear Rh(I) complexes [η⁵-C₅H₄(CH₂)₂Si(OMe)₃]Rh(CO)₂ (3). [η⁵-C₅H₄(CH₂)₂Si(OMe)₃]Rh(COD) (4) and [η⁵-C₅H₄(CH₂)₂Si(OMe)₃]Rh(CO)(PPh₃) (5). Upon entrapment of 3–5 in silica sol-gel matrices, air stable, leach-proof and recyclable catalysts 6–8 resulted. Their catalytic activities in some hydrogenation processes were compared with those of the non-immobilized complexes 3–5, as well as with those of homogeneous and heterogenized non-silylated analogs, 9–14.     

Angiotensin II and angiotensin-(1-7) inhibit the inner cortex Na+ -ATPase activity through AT2 receptor

In the present paper, the modulation of the basolateral membrane (BLM) Na⁺-ATPase activity of inner cortex from pig kidney by angiotensin II (Ang II) and angiotensin-(1–7) (Ang-(1–7)) was evaluated. Ang II and Ang-(1–7) inhibit the Na⁺-ATPase activity in a dose-dependent manner (from 10⁻¹¹ to 10⁻⁵ M), with maximal effect obtained at 10⁻⁷ M for both peptides. Pharmacological evidences demonstrate that the inhibitory effects of Ang II and Ang-(1–7) are mediated by AT₂ receptor: The effect of both polypeptides is completely reversed by 10⁻⁸ M PD 123319, a selective AT₂ receptor antagonist, but is not affected by either (10⁻¹²–10⁻⁵ M) losartan or (10⁻¹⁰–10⁻⁷ M) A779, selective antagonists for AT₁ and AT_(1–7) receptors, respectively. The following results suggest that a PTX-insensitive, cholera toxin (CTX)-sensitive G protein/adenosine 3′,5′-cyclic monophosphate (cAMP)/PKA pathway is involved in this process: (1) the inhibitory effect of both peptides is completely reversed by 10⁻⁹ M guanosine 5′-O-(2-thiodiphosphate) (GDPβS; an inhibitor of the G protein activity), and mimicked by 10⁻¹⁰ M guanosine 5′-O-(3-thiotriphosphate) (GTPγS; an activator of the G protein activity); (2) the effects of both peptides are mimicked by CTX but are not affected by PTX; (3) Western blot analysis reveals the presence of the G_s protein in the isolated basolateral membrane fraction; (4) (10⁻¹⁰–10⁻⁶ M) cAMP has a similar and non-additive effect to Ang II and Ang-(1–7); (5) PKA inhibitory peptide abolishes the effects of Ang II and Ang-(1–7); and (6) both angiotensins stimulate PKA activity.     

Autoradiographic Visualization of the Receptor Subclasses for Vasoactive Intestinal Polypeptide (VIP) in Rat Brain

Vertongen, P., S. N. Schiffmann, P. Gourlet and P. Robberecht. Autoradiographic visualization of the receptor subclasses for Vasoactive Intestinal Polypeptide (VIP) in rat brain. Peptides 18(10) 1547–1554, 1997.—Vasoactive Intestinal Polypeptide (VIP) exerts its biological effects through interaction with two high affinity receptors named the VIP₁- and the VIP₂ receptors. Their messenger RNAs have been mapped in rat brain by in situ hybridization. A cyclic peptide (RO 25-1553) and a secretin analogue ([R¹⁶]chicken secretin) were identified as selective agonist peptides for the VIP₂- and VIP₁ receptors, respectively. The iodinated peptides retained the high affinity and selectivity of the unlabelled peptides and were used for the mapping of each receptor subclass in rat brain. VIP₁ receptors were present in the cerebral cortex, the piriform cortex, the claustrum, the caudate-putamen, the dentate gyrus, the lateral amygdaloïd nucleus, the anteroventral thalamic nucleus, the rhomboïd nucleus, the supraoptic nucleus and the choroïd plexus. VIP₂ receptors were present in the cerebral cortex, the claustrum, the caudate-putamen, the nucleus accumbens, the lateral septal nuclei, the bed nucleus of the stria terminalis, the basolateral amygdaloïd nucleus, the Ammon’s horn, the thalamic nuclei except some centromedial nuclei, the medial habenula, the suprachiasmatic nucleus, the periventricular nucleus, the mammilary nucleus, the superior colliculus and the choroïd plexus.     

A series of heteroleptic complexes of the type fac-[MnL2] [H2L=derivatives of N-(2-hydroxybenzyl)glycine or N-(5-nitro-2-hydroxybenzyl)sarcosine] possessing unusual Mn(III) co-ordination spheres

The mononuclear manganese(III) complexes [C₅H₁₀NH₂][MnL₂] [L²⁻=a substituted N-(2-hydroxybenzyl)glycinate (hbg²⁻) viz. 3,5-dibromo- (3,5-Br-hbg²⁻), 3,5-dichloro- (3,5-Cl-hbg²⁻), 3-methyl-5-chloro- (3,5-Me,Cl-hbg²⁻), 5-bromo- (5-Br-hbg²⁻), 5-chloro- (5-Cl-hbg²⁻), 5-nitro- (5-NO₂-hbg²⁻) or N-(5-nitro-2-hydroxybenzyl)sarcosine (5-NO₂-hbs²⁻)] have been synthesised by reaction of the appropriate ligand with manganese(II) perchlorate under ambient conditions in a 2:1 molar ratio using piperidine as base. The structures of three of these complexes, [C₅H₁₀NH₂][Mn(3,5-Cl-hbg)₂] (2), [C₅H₁₀NH₂][Mn(5-NO₂-hbg)₂] (6) and [C₅H₁₀NH₂][Mn(5-NO₂-hbs)₂] (7) have been elucidated by single-crystal X-ray crystallography and each displays two similar, independent [MnL₂]⁻ ions in the asymmetric unit linked via piperidinium cations through hydrogen bonding. The ligands co-ordinate in a facial tridentate fashion with the three donor atoms being the phenolate and carboxylate oxygens and the amine nitrogen. The geometry at the Mn centres is compressed rhombic octahedral consistent with a pseudo-Jahn–Teller compression along the Mn–O(phenolate) axis. Mean bond lengths are in the ranges 1.886–1.889 Å for the Mn–O(phenolate), 2.062–2.125 Å for the Mn–O(carboxylate) and 2.091–2.184 Å for the Mn–N(amine) distances. The magnetic susceptibility and electronic and IR spectroscopic data are discussed with reference to the crystal structures.     

Synthesis and characterization of homologous nickel(II) and palladium(II) complexes with biphosphine monoxide ligands Ph2P(CH2)nP(O)Ph2 (n = 1–3) and pTol2P(CH2)P(O)pTol2

A series of cationic nickel complexes [(η³-methally)Ni(PP(O))]SbF₆ (1–4) [PP(O) = Ph₂P(CH₂)P(O)Ph₂ (dppmO) (1), Ph₂P(CH₂)₂P(O)Ph₂ (dppeO) (2), Ph₂P(CH₂)₃P(O)Ph₂ (dpppO) (3), pTol₂P(CH₂)P(O)pTol₂ (dtolpmO) (4)] has been synthesized in good yields by treatment of [(η³-methally)NiBr]₂ with biphosphine monoxides and AgSbF₆. The ligands are coordinated in a bidentate way. Starting from [(η³-all)PdI]₂ the cationic complexes [(η³-all)PP(O))]Y (8–14). [PP(O) = dppmO, dppeO, dpppO, dtolpmO;Y = BF₄, SbF₆, CF₃SO₃, pTolSO₃] were synthesized in good yields. The coordination mode of the ligand is dependent on the backbone and the anion, revealing a monodentate coordination with dppmO for stronger coordinating anions. The intermediates [(η³-all)Pd(I)(PP(O)-κ¹-P)] (5–7) [PP(O) = dppmO (5), dppeO (6), dtolpmO (7)] were isolated and characterized. Neutral methyl complexes [(Cl)(Me)Pd(PP(O))] (15–18). [PP(O) = dppmO (15), dppeO (16), dpppO (17), dtolpmO (18)] can easily be obtained in high yields starting from [(cod)PdCl₂]. For dppmO two different routes are presented. The structure of [(Me)(Cl)Pd{;Ph₂P(CH₂-P(O)Ph₂-κ²-P,O};] · CH₂Cl₂ (15) with the chlorine atom trans to phosphorus was determined by X-ray diffraction.     

Biological activities of synthetic analogues of Alternaria alternata toxin (AAL-toxin) and fumonisin in plant and mammalian cell cultures

In a search for an analogue of AAL-toxin with high phytotoxicity and low mammalian toxicity, aminopentols [(AP₁), hexacetyl AP₁ and N-acetyl AP₁], and nine analogues (1–9), were tested for toxicity to duckweed (Lemna pausicostata), susceptible tomato (asc/asc) leaf discs, black nightshade leaf discs and mammalian cell lines, including dog kidney (MDCK), rat liver hepatoma (H4TG) and mouse fibroblasts (NIH3T3). These were compared with AAL-toxin and fumonisin B₁ (FB₁). Analogue 9 at 10 μM increased cellular leakage and chlorophyll loss from both tomato and black nightshade leaf discs. The diester 9 was the most active in the duckweed bioassay, but it was much less toxic to MDCK and H4TG cells with an IC₅₀ of 200 μM compared to 10 μM for FB₁. Analogue 9 and FB₁ showed similar low toxicities (IC₅₀ = 150 μM) to NIH3T3 cells. Among the substances tested, only analogue 9 had significant phytotoxicity and low mammalian toxicity, indicating some potential for development of safe and effective natural herbicides.     

Comparison between the surface plasmon resonance (SPR) and the quartz crystal microbalance (QCM) method in a structural analysis of human endothelin-1

In this study, an automated surface plasmon resonance (SPR)-based biosensor was compared with a quartz crystal microbalance (QCM) biosensor. The two biosensor systems were used for characterizing a site-directed monoclonal antibody (mAb), raised against the C-terminal heptapeptide ET-1_15–21 of the human endothelin (ET-1). The mAb was characterized by its capacity for binding to ET-1, ET-3, Big.ET-1_22–38, the C-terminal (ET-1_15–21, ET-1_16–21, ET-1_17–21), and six derivates of ET-1_16–21, each containing a substitution with alanine (Ala) of a single aminoacid from position 16–21, respectively. The mAb reacted well with ET-1 and its fragments ET-1_15–21, ET-1_16–21, ET-1_17–21, but showed only a partial cross-reaction with ET-3, and did not bind human Big.ET-1_22–38. The Ala substitution on position 16,17, or 19 of ET-1_16–21 did not affect the antibody binding capacity of the hexapaptide ET-1_16–21. On the contrary, Ala substitution or Asp¹⁸, Ile²⁰ and particularly Trp²¹, inhibited its immunoreactivity. Thus the C-terminal represents an immunodominant epitope in ET-1 and is important for antibody binding. The SPR and QCM response signals were similar in shape but differing in time scales, reflecting differences in detection mechanisms. With regard to the fundamental problem of comparing different measurement principles, we found a good correlation between results obtained using the BIA technology and the QCM.     

Interactions between thiamine and large anions. Crystal structures of (H-thiamine)[Pt(SCN)4] · 3H2O and (H-thiamine)[Pt(SCN)6] · H2O

The reaction of thiamine with K₂Pt^IICl₄ and with Pt^IVCl₄ in the presence of excess NaSCN in aqueous solution gave thiamine salts, (H-thiamine)[Pt(SCN)₄] · 3H₂O (1) and (H-thiamine)[Pt(SCN)₆] · H₂O (2), respectively, structures of which have been determined by X-ray diffraction. The thiamine molecule adopts the usual F conformation in each salt. In 1, [Pt(SCN)₄]²⁻ ions act as large planar spacers in the crystal lattice and interact scarcely with thiamine, except for a hydrogen bonding with the terminal hydroxy O(5γ). Instead, water molecules form two types of host–guest-like interactions with the pyrimidine and the thiazolium moieties of a thiamine molecule, one being a C(2)–Hwaterpyrimidine bridge and the other being an N(4′)–Hwaterthiazolium bridge. In 2, despite the much larger ion size, octahedral [Pt(SCN)₆]²⁻ ions form a C(2)–Hanionpyrimidine bridge and an N(4′)–Hanionthiazolium bridge. An additional hydrogen bonding between the anion and the terminal O(5γ) of thiamine creates a hydrogen-bonded macrocyclic ring {thiaminium–[Pt(SCN)₆]²⁻}₂, a supramolecule.     

Steric control in the formation of Co2(CO)6-alkyne complexes from Group 14 tetraalkynes and their reactions with acid

A series of tetrakis(trimethylsilylethyne) derivatives of Group 14 metals (2–4) was prepared. Co₂(CO)₆ complexes 5–10 were synthesised by the reaction of 2–4 with Co₂(CO)₈. From the silyl and germyl based compounds 2 and 3, either one or two alkynes could be complexed with Co₂(CO)₆. In contrast, the tin derived compound 4 could accommodate up to four Co₂(CO)₆ complexes. The longest wavelength UV-Vis absorbances of the silicon and germanium-based complexes were consistent with multiple, non-conjugated Co₂(CO)₆ chromophores. The tetrakis Co₂(CO)₆ complex 10, however, absorbs at a much longer wavelength suggesting conjugation of Co₂(CO)₆ complexes through the tin. The reactivity towards protonolysis of the uncomplexed alkynes 2–4 is a consequence of the hyperconjugative stabilisation of the intermediate β-vinyl cation (the β-effect): Sn(CCSiMe₃)₃>SnOTf(CCSiMe₃)₂>SiMe₃>Ge(CCSiMe₃)₃. The reactivity of the Co₂(CO)₆ complexes, however, was quite different from the reactions of 2–4 and from analogous all-carbon systems. Treatment of 5–10 with strong acid led neither to protiodemetallation of the complexed or non-complexed alkynes but to decomplexation of the cobalt. Similarly, ligand metathesis reactions between 10 and Ph₂SiCl₂ were not observed. The normal reactivity of silylalkynes towards electrophiles, which was expected to be enhanced by the presence of the cobalt complex, was diminished by the particular steric environment of the molecules under examination (5–10). As a result, the favoured reaction under these conditions was decomplexation of the cobalt.     

The F1-ATPase beta-subunit is the putative enterostatin receptor

It has been suggested that the F₁-ATPase β-subunit is the enterostatin receptor. We investigated the binding activity of the purified protein with a labeled antagonist, β-casomorphin_1–7, in the absence and presence of cold enterostatin. ¹²⁵I-β-casomorphin_1–7 weakly binds to the rat F₁-ATPase β-subunit. Binding was promoted by low concentrations of cold enterostatin but displaced by higher concentrations. To study the relationship between binding activity and feeding behavior, we examined the ability of a number of enterostatin analogs to affect β-casomorphin_1–7 binding to the F₁-ATPase β-subunit. Peptides that suppressed food intake promoted β-casomorphin_1–7 binding whereas peptides that stimulated food intake or did not affect the food intake displaced β-casomorphin_1–7 binding. Surface plasmon resonance measurements show that the β-subunit of F₁-ATPase binds immobilized enterostatin with a dissociation constant of 150 nM, where no binding could be detected for the assembled F₁-ATPase complex. Western blot analysis showed the F₁-ATPase β-subunit was present on plasma and mitochondrial membranes of rat liver and amygdala. The data provides evidence that the F₁-ATPase β-subunit is the enterostatin receptor and suggests that enterostatin and β-casomorphin_1–7 bind to distinct sites on the protein.     

The structure of the dichromium compound Cr2(μ-OH)2(μ-3,5Cl2-form)2(η-3,5Cl2-form)2

With exposure to trace amounts of air and moisture, the Cr₂(II, II) complex Cr₂(μ-3,5Cl₂-form)₄, where 3,5Cl₂-form is [(3,5-Cl₂C₆H₃)NC(H)N(3,5-Cl₂C₆H₃)⁻], undergoes an oxidative addition reaction. Structural information from the X-ray crystal structure of the edge-sharing bioctahedral (ESBO) Cr₂(III, III) product Cr₂(μ-OH)₂(μ-3,5Cl₂-form)₂(η²-3,5Cl₂-form)₂ (1) indicates 1 has a significantly longer Cr–Cr distance [2.732(2) Å] than Cr₂(μ-3,5Cl₂-form)₄ [1.9162(10) Å], but the shortest Cr–Cr distance in an ESBO Cr₂(III, III) complex recorded to date.     

Mode of binding of [3H]dibenzocycloalkenimine (MK-801) to the N-methyl-D-aspartate (NMDA) receptor and its therapeutic implication

Binding of the labeled anticonvulsant drug [³H]dibenzocycloalkenimine (³H]MK-801) to the N-methyl-D-aspartate (NMDA) receptor and its dissociation from the receptor at 25°C are slow processes, both of which follow first order kinetics (t_1/270 and 180 min, respectively). Both reactions are markedly accelerated by glutamate and glycine (t_1/22-8 and 4 min, respectively), which allow bimolecular association kinetics of the labeled drug with the receptors whereas equilibrium binding of [³H]MK-801 (K_d 2–4 nM) is hardly affected by glutamate and glycine. The data suggest that MK-801 acts as a steric blocker of the NMDA receptor channel. The competitive antagonist D-(−)-2-amino-5-phosphovaleric acid (AP-5) freezes the receptor in a state which precludes either binding of [³H]MK-801 to the receptor channel or its dissociation from it. These findings have therapeutic implications.